Fetal therapy for Down syndrome: an ethical exploration

Area of Science:

• Medical Ethics
• Genetics
• Developmental Biology

Background:

• Advances in prenatal screening for Down syndrome (DS) coincide with developing therapies for various aspects of the condition.
• Intellectual disability is a primary concern, driving research into interventions.
• Hypotheses suggest prenatal interventions may offer better cognitive improvement in individuals with DS compared to postnatal treatments.

Purpose of the Study:

• To ethically evaluate the concept of improving cognitive function in individuals with DS.
• To explore ethical considerations surrounding the development of fetal therapy for DS (FTDS).

Main Methods:

• Ethical analysis of cognitive improvement interventions for DS.
• Exploration of ethical aspects of fetal therapy for DS (FTDS).

Main Results:

• Therapy targeting cognitive improvement in DS is ethically justifiable, except under a narrow social model of disability.
• The ethical permissibility of FTDS is contingent on rigorous ethical evaluation.

Conclusions:

• FTDS research participation requires robust preclinical data and clear communication to prevent therapeutic misconception.
• If FTDS is proven safe and effective, pregnant women diagnosed with trisomy 21 who opt to continue the pregnancy may have a moral imperative to consider it.